EP Patent

EP1666043A1 — Product containing prostaglandin

Assigned to Santen Pharmaceutical Co Ltd · Expires 2006-06-07 · 20y expired

What this patent protects

For the purpose of the storage in a stable manner of an aqueous liquid preparation containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water, an object of the present invention is to inhibit the decrease of the content of the…

USPTO Abstract

For the purpose of the storage in a stable manner of an aqueous liquid preparation containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water, an object of the present invention is to inhibit the decrease of the content of the prostaglandin derivative that is an active ingredient in the aqueous liquid preparation, taking into account of the material of the resin container. According to the present invention, a prostaglandin-containing product is provided, wherein an aqueous liquid preparation containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water is stored in a resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate, thereby inhibiting the decrease of the content of the prostaglandin derivative in the aqueous liquid preparation.

Drugs covered by this patent

Patent Metadata

Patent number
EP1666043A1
Jurisdiction
EP
Classification
Expires
2006-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Santen Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.